14F7 Anti-GM3(NeuGc)ganglioside. PMID: 10954880
Key role of a structural water molecule for the specificity of 14F7-An antitumor antibody targeting the NeuGc GM3 ganglioside. PMID: 34735569
Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 Ganglioside in retinoblastoma tumours. PMID: 25403557
Prognostic Role of 14F7 Mab Immunoreactivity against N-Glycolyl GM3 Ganglioside in Colon Cancer. PMID: 24639871
Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody. PMID: 26181624
Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin. PMID: 26317019
Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Primary Lymphoid Tumors and Lymph Node Metastasis. PMID: 24381785
Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System. PMID: 21991524
Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms. PMID: 22363862
Immunoreactivity of the 14F7 Mab (Raised against N-Glycolyl GM3 Ganglioside) as a Positive Prognostic Factor in Non-Small-Cell Lung Cancer. PMID: 22482082
Structure and molecular interactions of a unique antitumor antibody specific for N-glycolyl GM3. PMID: 14627696
Crystal structure of an L chain optimised 14F7 anti-ganglioside Fv suggests a unique tumour-specificity through an unusual H-chain CDR3 architecture. PMID: 30022069
Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. PMID: 16322892
Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside specificities. PMID: 23138862
A shift from N-glycolyl- to N-acetyl-sialic acid in the GM3 ganglioside impairs tumor development in mouse lymphocytic leukemia cells. PMID: 23547010
Insights into the immunogenetic basis of two ganglioside-associated idiotypic networks. PMID: 17270710
In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. PMID: 12573110
Generation and characterization of an anti-idiotype monoclonal antibody related to GM3(NeuGc) ganglioside. PMID: 14678648
Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences. PMID: 26634172
Light-chain shuffling results in successful phage display selection of functional prokaryotic-expressed antibody fragments to N-glycolyl GM3 ganglioside. PMID: 15541278
A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates. PMID: 21802167
Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer. PMID: 21941577
A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. PMID: 10952412
Cytofluorimetric evaluation of N-glycolylated GM3 ganglioside expression on murine leukocytes. PMID: 21324343
Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas. PMID: 31182063
N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese. PMID: 22574836
Switching on cytotoxicity by a single mutation at the heavy chain variable region of an anti-ganglioside antibody. PMID: 21306777
Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry. PMID: 19435393
Hypothesis: Hypoxia induces de novo synthesis of NeuGc gangliosides in humans through CMAH domain substitute. PMID: 29196263
Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines. PMID: 19951433
CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues. PMID: 35990626
Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3. PMID: 29844873
Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment., PMID:34516533
Aberrant expression of N-glycolyl GM3 ganglioside is associated with the aggressive biological behavior of human sarcomas., PMID:31182063
Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients., PMID:29936534
Immunologic Response Elicited in Breast Cancer Patients Receiving a NeuGcGM3-based Vaccine as Adjuvant Therapy., PMID:28604556
Frequent co-expression of EGFR and NeuGcGM3 ganglioside in cancer: it's potential therapeutic implications., PMID:27449755
Racotumomab for treating lung cancer and pediatric refractory malignancies., PMID:26903265
Anti-NeuGcGM3 reactivity: a possible role of natural antibodies and B-1 cells in tumor immunosurveillance., PMID:26214505
A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies., PMID:26154941
Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer., PMID:25420897
Immunoreactivity of the 14F7 Mab raised against N-Glycolyl GM3 Ganglioside in retinoblastoma tumours., PMID:25403557
Racotumomab - a novel anti-idiotype monoclonal antibody vaccine for the treatment of cancer., PMID:24918647
A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients., PMID:24788102
Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3., PMID:23335925
Human antibodies reactive to NeuGcGM3 ganglioside have cytotoxic antitumor properties., PMID:23319307
Immune response to racotumomab in a child with relapsed neuroblastoma., PMID:23267436
Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer., PMID:23162791
Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data., PMID:23110257
Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma., PMID:23055778
NGlycolylGM3/VSSP Vaccine in Metastatic Breast Cancer Patients: Results of Phase I/IIa Clinical Trial., PMID:23055739
N-Glycolyl GM3 ganglioside immunoexpression in oral mucosal melanomas of Chinese., PMID:22574836
P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties., PMID:22566972
Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms., PMID:22363862
Immunoreactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Epithelial Malignant Tumors from Digestive System., PMID:21991524
Detection of N-glycolyl GM3 ganglioside in neuroectodermal tumors by immunohistochemistry: an attractive vaccine target for aggressive pediatric cancer., PMID:21941577
Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism., PMID:21300821
Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients., PMID:20855939
Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines., PMID:19951433
Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody., PMID:19748674
Detection and characterization of N-glycolyated gangliosides in Wilms tumor by immunohistochemistry., PMID:19435393
Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma., PMID:19066887
Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody., PMID:18941253
Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study., PMID:18285705
Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial., PMID:17218777
Incorporation, remodeling and re-expression of exogenous gangliosides in human cancer cell lines in vitro and in vivo., PMID:15279066
Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides., PMID:12763476
Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine., PMID:12637465
Lack of antibody production against Hanganutziu-Deicher (H-D) antigens with N-glycolylneuraminic acid in patients with porcine exposure history., PMID:11021662
Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides., PMID:9621110
Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids., PMID:8770642
Antigen-specific primary immune response of human B-lymphocytes after in vitro immunization with GM3 ganglioside., PMID:8597625
The addition of exogenous gangliosides to cultured human cells results in the cell type-specific expression of novel surface antigens by a biosynthetic process., PMID:2464027
Analysis of the expression of N-glycolylneuraminic acid-containing gangliosides in cells and tissues using two human monoclonal antibodies., PMID:3192544
Antiglycolipid antibodies in normal and pathologic human sera and synovial fluids., PMID:4060695
For research use only. Not for human or drug use.
